微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2025, Vol. 17 ›› Issue (6): 739-746.doi: 10.3969/j.issn.1674-5671.2025.06.11

• 综述 • 上一篇    下一篇

抗体偶联药物在非小细胞肺癌联合治疗中的临床实践与挑战

  

  1. 山东第一医科大学附属省立医院病理科；菏泽市牡丹人民医院病理科
  • 出版日期:2025-12-25 发布日期:2026-02-02
  • 通讯作者: 许雅丽 E-mail:Skyelia@sina.com
  • 基金资助:
    山东省自然科学基金联合基金项目(ZR2022LSW001)


Clinical practice and challenges of antibody⁃drug conjugate in combination therapy for non⁃small cell lung cancer

  • Online:2025-12-25 Published:2026-02-02
  • Supported by:

PDF (PC)

1

赞

摘要： 抗体偶联药物（antibody⁃drug conjugate, ADC）通过靶向肿瘤细胞递送强效细胞毒性药物，实现对非小细胞肺癌（non⁃small cell lung cancer，NSCLC）的精准杀伤，但其单药疗法因肿瘤异质性和获得性耐药而受限。近年来，ADC与免疫检查点抑制剂及靶向药物联合应用的策略，在驱动基因阴性NSCLC中表现出优异的疗效。这一策略不仅为该类患者提供了一种可去化疗的新型治疗模式，也显著改变了晚期NSCLC的治疗格局。本文旨在系统综述ADC联合治疗的生物学机制以及最新临床研究进展，并探讨其面临的关键挑战与未来应对措施，以期为晚期NSCLC的精准治疗提供理论依据与临床实践参考。

关键词: 非小细胞肺癌, 抗体偶联药物, 联合治疗, 精准医学

Abstract: Antibody⁃drug conjugate (ADC) facilitate precise targeting of non⁃small cell lung cancer (NSCLC) by delivering potent cytotoxic agents directly to tumor cells, but monotherapy with ADC limited by tumor heterogeneity and acquired resistance. In recent years, combination therapy strategies that integrate ADC with immune checkpoint inhibitors and targeted agents have demonstrated superior efficacy in driver gene⁃negative NSCLC. This approach not only offers a chemotherapy⁃sparing treatment model, but also significantly transforms the therapeutic landscape for advanced NSCLC. This review aims to systematically summarize the biological mechanisms and the latest clinical advances of ADC⁃based combination therapy, while also exploring key challenges and future directions. It seeks to provide a theoretical foundation and clinical practical insights for precision treatment in advanced NSCLC.

Key words: Non?small cell lung cancer, Antibody?drug conjugate, Combination therapy, Precision medicine

中图分类号: 

  • R734.2